AstraZeneca PLC (AZN) Release: New Data Suggest Patient Smoking Habits Had No Impact on PLATO Study Findings of a Greater Reduction in Thrombotic Cardiovascular Events with BRILINTA (ticagrelor) Compared to Clopidogrel  
9/6/2012 10:20:55 AM

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced results from a PLATO sub-analysis that evaluated the effect of smoking status on clinical outcomes in patients with acute coronary syndrome (ACS). This analysis suggests the overall findings from the PLATO study of greater reduction in thrombotic CV events with BRILINTA® (ticagrelor) tablets plus aspirin compared to clopidogrel plus aspirin was consistent regardless of smoking habits. 1 These data, slated for publication in the September issue of American Heart Journal, are currently available online, and were previously presented at the American College of Cardiology 2012 meeting.